Sunday, March 16, 2025, Seattle, Washington, 12:30 PM – 2:00 PM Pacific Time (3:30 PM – 5:00 PM Eastern Time)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Care of Patients with Ovarian Cancer

An Independent CME Symposium During the 2025 SGO Annual Meeting on Women’s Cancer®

Register for in-person Register for webcast

Location
Seattle Convention Center
705 Pike Street
Seattle, Washington
Phone: (206) 694-5000

Program Schedule — Pacific Time
12:00 PM – 12:30 PM — Registration and Lunch Buffet
12:30 PM – 2:00 PM — Educational Meeting

Meeting Room
Room 6AB – Level 6

There is no registration fee for this event. For the in-person symposium in Seattle, preregistration is required as seating is limited.  
 
Faculty
Kathleen N Moore, MD, MS
Deputy Director
Virginia Kerley Cade Chair in Developmental Therapeutics
Co-Director, Cancer Therapeutics Program
Stephenson Cancer Center at the
University of Oklahoma HSC
Associate Director, GOG Partners
Board of Directors, GOG Foundation
Board of Directors, ASCO
Oklahoma City, Oklahoma

Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California


Shannon N Westin, MD, MPH, FASCO, FACOG
Professor
Medical Director, Gynecologic Oncology Center
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator
Angeles Alvarez Secord, MD, MHSc
Professor of Obstetrics and Gynecology
Gynecologic Oncology
Director of Gynecologic Oncology Clinical Trials
Duke Cancer Institute
Durham, North Carolina




This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, and Mural Oncology Inc.
Program Schedule — Pacific Time
12:00 PM – 12:30 PM — Registration and Lunch Buffet
12:30 PM – 2:00 PM — Educational Meeting

Module 1: Up-Front Treatment for Advanced Ovarian Cancer (OC)

  • Optimal approaches to biomarker testing for patients with newly diagnosed advanced OC; significance of somatic and germline BRCA mutations and homologous recombination deficiency status for treatment decision-making
  • Long-term data with olaparib, niraparib and olaparib/bevacizumab maintenance therapy for patients with newly diagnosed OC; factors affecting selection among these strategies
  • Early findings with niraparib/bevacizumab maintenance after front-line platinum-based chemotherapy/bevacizumab; ongoing evaluation and potential clinical role
  • Biological rationale for combining PARP inhibitors with anti-PD-1/PD-L1 antibodies with or without bevacizumab for OC
  • Major efficacy and safety findings from the Phase III DUO-O study of up-front durvalumab in combination with chemotherapy and bevacizumab followed by durvalumab, bevacizumab and olaparib as maintenance therapy
  • Other ongoing Phase III research efforts evaluating PARP inhibitors in combination with immune checkpoint inhibitors for advanced OC; anticipated completion dates

Module 2: Management of Relapsed/Refractory OC

  • Long-term follow-up from pivotal trials evaluating PARP inhibitors for platinum-sensitive and platinum-resistant recurrent OC; implications of updated indications for these agents in relapsed disease
  • Clinical utility, if any, of rechallenge with a PARP inhibitor for patients who have experienced disease progression on or after prior PARP inhibitor therapy
  • Incidence and clinical relevance of folate receptor alpha (FRα)-positive OC; optimal approaches to and timing of FRα testing
  • Available efficacy and safety data, including findings from the Phase III MIRASOL trial, with mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant OC
  • Available findings from the Phase II PICCOLO trial of mirvetuximab soravtansine for FRα-positive, platinum-sensitiveOC; ongoing Phase III evaluation and potential clinical role in this setting
  • Optimal integration of mirvetuximab soravtansine into OC management algorithms
  • Prevalence of HER2 overexpression in advanced OC; outcomes achieved with trastuzumab deruxtecan (T-DXd) among patients with advanced HER2-positive OC in the DESTINY-PanTumor02 study
  • Recent FDA approval of T-DXd for pretreated HER2-positive solid tumors; implications for OC management

Module 3: Novel Investigational Therapies for Advanced OC

  • Frequency of CDH6 expression in OC; mechanism of antitumor activity of the novel CDH6-directed antibody-drug conjugate raludotatug deruxtecan (R-DXd)
  • Early research findings with R-DXd for patients with heavily pretreated platinum-resistant advanced OC
  • Ongoing evaluation of R-DXd for platinum-resistant advanced OC in the Phase II/III REJOICE-Ovarian01 trial
  • Mechanism of action of the novel engineered cytokine nemvaleukin alfa
  • Activity and safety observed with nemvaleukin alfa in combination with pembrolizumab in the platinum-resistant OC cohort of the Phase I/II ARTISTRY-1 study
  • Design, eligibility criteria and primary and secondary endpoints of the Phase III ARTISTRY-7 trial of nemvaleukin alfa/pembrolizumab versus chemotherapy for platinum-resistant advanced OC; estimated completion date
  • Other novel agents and strategies under evaluation for the treatment of advanced OC

Module 4: Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC

  • Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors in patients with OC
  • Reported risk of long-term serious side effects, such as acute myeloid leukemia and myelodysplastic syndromes, with PARP inhibitor therapy
  • Initial dosing of approved PARP inhibitors and appropriate dose-modification strategies for patients experiencing treatment-related toxicity
  • Pathogenesis and incidence of ocular adverse reactions associated with mirvetuximab soravtansine, such as visual impairment, keratopathy, dry eye, photophobia, eye pain and uveitis
  • Recommended approaches to monitoring for, preventing and ameliorating mirvetuximab soravtansine-associated ocular toxicities
  • Spectrum, frequency, severity and management of other side effects, such as peripheral neuropathy, pneumonitis and gastrointestinal toxicities, in patients receiving mirvetuximab soravtansine

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of ovarian cancer (OC).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced OC, and as appropriate, counsel patients regarding personalized treatment recommendations.
  • Assess available clinical trial data with and newly adapted indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC to optimally and appropriately incorporate these agents into management algorithms.
  • Evaluate the biological rationale for and published research data with PARP inhibitors in combination with other systemic therapies, and consider the current and future clinical and research implications of these findings on OC management.
  • Appraise relevant biological and patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
  • Recognize the rationale for targeting folate receptor alpha (FRα) in OC, and determine effective methods to test for this newly relevant biomarker.
  • Understand the mechanism of action of and current research findings with antibody-drug conjugates directed at FRα, and optimally integrate these agents into the care of patients with recurrent OC.
  • Appreciate side effects associated with various systemic therapies commonly employed in the management of OC, and use this information to develop supportive care plans for patients undergoing treatment with these agents.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for OC, and as appropriate, counsel patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY The following faculty reported relevant financial relationships with ineligible entities:

Dr MooreAdvisory Committees: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Blueprint Medicines, Caris Life Sciences, Corcept Therapeutics, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Janssen Biotech Inc, Lilly, Merck, Mersana Therapeutics Inc, Novartis, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Allarity Therapeutics, Daiichi Sankyo Inc, GSK, ImmunoGen Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics. Dr SalaniAdvisory Committees: AbbVie Inc, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, Merck, Pfizer Inc. Dr WestinConsulting Agreements: AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Clovis Oncology, Corcept Therapeutics, Daiichi Sankyo Inc, Eisai Inc, EQRx, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Seagen Inc, Verastem Inc, Vincerx Pharma, Zentalis Pharmaceuticals, ZielBio; Contracted Research (to Institution): AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings, Clovis Oncology, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Zentalis Pharmaceuticals.

MODERATOR Dr SecordAdvisory Boards (Honorarium): AbbVie Inc; Advisory Boards (Uncompensated): AstraZeneca Pharmaceuticals LP, CanariaBio Inc, Clovis Oncology, Gilead Sciences Inc, GSK, ImmunoGen Inc, Imvax Inc, Merck, Mersana Therapeutics Inc, Natera Inc, OncoQuest Inc; Clinical Trial Steering Committees (Uncompensated): CanariaBio Inc (FLORA-5 trial, QPT-ORE-004 trial), VBL Therapeutics (OVAL trial); Clinical Trial and Research Grant Funding (to Institution): AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Ellipses Pharma, Genentech, a member of the Roche Group, GSK, I-Mab Biopharma, ImmunoGen Inc, Karyopharm Therapeutics, Merck, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, OncoQuest Inc, Seagen Inc, VBL Therapeutics, Zentalis Pharmaceuticals; Nonrelevant Financial Relationships: GOG Foundation, Foundation for Women’s Cancer, National Clinical Trials Network, NRG Oncology, Society of Gynecologic Oncology, UpToDate.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, and Mural Oncology Inc.

Seattle Convention Center
705 Pike Street
Seattle, WA 98101
Phone: (206) 694-5000

Meeting Room
Room 6AB – Level 6

Directions
The Seattle Convention Center, formerly the Washington State Convention Center, is the main venue for the 2025 SGO Annual Meeting on Women’s Cancer.

 
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of ovarian cancer.

There is no registration fee for this event. For the in-person symposium in Seattle, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2025 SGO Annual Meeting on Women’s Cancer®.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.